406 related articles for article (PubMed ID: 38590525)
1. Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients.
Al-Danakh A; Safi M; Jian Y; Yang L; Zhu X; Chen Q; Yang K; Wang S; Zhang J; Yang D
Front Immunol; 2024; 15():1348189. PubMed ID: 38590525
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study.
Al-Danakh A; Safi M; Alradhi M; Chen Q; Baldi S; Zhu X; Yang D
Cells; 2022 Nov; 11(22):. PubMed ID: 36429070
[No Abstract] [Full Text] [Related]
3. Combined Assessment of the Tumor-Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer.
Ravensbergen CJ; Polack M; Roelands J; Crobach S; Putter H; Gelderblom H; Tollenaar RAEM; Mesker WE
Cells; 2021 Oct; 10(11):. PubMed ID: 34831157
[TBL] [Abstract][Full Text] [Related]
4. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M;
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586
[TBL] [Abstract][Full Text] [Related]
5. Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors.
Zhou JG; Donaubauer AJ; Frey B; Becker I; Rutzner S; Eckstein M; Sun R; Ma H; Schubert P; Schweizer C; Fietkau R; Deutsch E; Gaipl U; Hecht M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33593828
[TBL] [Abstract][Full Text] [Related]
6. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study.
Safi M; Jin C; Aldanakh A; Feng P; Qin H; Alradhi M; Zhang L; Zhang J; Adlat S; Zhao Y; Liu J
BMC Cancer; 2022 Sep; 22(1):978. PubMed ID: 36100891
[TBL] [Abstract][Full Text] [Related]
8. Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI)
Safi M; Al-Azab M; Jin C; Trapani D; Baldi S; Adlat S; Wang A; Ahmad B; Al-Madani H; Shan X; Liu J
Front Immunol; 2021; 12():609728. PubMed ID: 34887846
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. TNF in the era of immune checkpoint inhibitors: friend or foe?
Chen AY; Wolchok JD; Bass AR
Nat Rev Rheumatol; 2021 Apr; 17(4):213-223. PubMed ID: 33686279
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Geriatric Oncology.
Cook SL; Al Amin M; Bari S; Poonnen PJ; Khasraw M; Johnson MO
Curr Oncol Rep; 2024 May; 26(5):562-572. PubMed ID: 38587598
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology.
Choucair K; Naqash AR; Nebhan CA; Nipp R; Johnson DB; Saeed A
Oncologist; 2022 Sep; 27(9):778-789. PubMed ID: 35781739
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K; Sakaeda K; Fukuda M; Sakai Y; Yamaguchi H; Takemoto S; Shimizu K; Masuda T; Nakatomi K; Kawase S; Tanaka R; Suetsugu T; Mizuno K; Hasegawa T; Atarashi Y; Irino Y; Sato T; Inoue H; Hattori N; Kanda E; Nakata M; Mukae H; Oga T; Oka M
Adv Clin Chem; 2023; 112():155-204. PubMed ID: 36642483
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis.
Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X
Front Immunol; 2021; 12():730320. PubMed ID: 34646270
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
Moturi K; Sharma H; Hashemi-Sadraei N
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
[TBL] [Abstract][Full Text] [Related]
20. Immune Aging and Immunotherapy in Cancer.
Kaiser M; Semeraro MD; Herrmann M; Absenger G; Gerger A; Renner W
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]